Biotech | October 26, 2021
Biological E to receive US $ 50 million to boost Covid-19 vaccine capacity
Support from DFC will help produce one billion vaccine doses by the end of 2022
Support from DFC will help produce one billion vaccine doses by the end of 2022
The list of kids with co-morbidities eligible for vaccination would be announced by the government
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
Pluss Advanced Technologies (PLUSS), has led the growth of energy storage materials across applications. Their proprietary Phase Change Material has gained wide acceptance in the pharmaceutical, logistics and food industries. The varied demands of the industry during Covid-19 has brought its technology into focus. Samit Jain, MD, PLUSS in conversation with Thomas C Thottathil discusses trends and outlines his plans for the business
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
This unique record was made possible by collating hard copies of the books in a structured manner
The company is continuing with the evaluation of canakinumab in lung cancer, and is applying findings to the overall lung cancer development plan
Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
The test combines sensitivity with speed and is designed to be used in health care settings to aid with rapid diagnosis of Covid-19
Subscribe To Our Newsletter & Stay Updated
